Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 19/20 | 0.58 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.58 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.58 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.58 |
| ▸ | NQO2 | P16083 | 1/20 | 0.58 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.58 |
| ▸ | ACTR2 | P61160 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5317983 | 0.88 | ADRB2 (0.46) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL5201214 | 0.84 | MAPK14 (0.73) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL31046795 | 0.84 | MAPK14 (0.73) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL5201395 | 0.78 | MAPK14 (0.63) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL1810732 | 0.78 | PSEN1 (0.55) | EPHX2 | |
| SCHEMBL5323864 | 0.78 | MAPK14 (0.49) | MAPK14EPHX2 | |
| SCHEMBL1810470 | 0.78 | PSEN1 (0.51) | EPHX2 | |
| SCHEMBL5204563 | 0.77 | MAPK14 (0.64) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL5202271 | 0.77 | MAPK14 (0.66) | MAPK14MAPK11MAPK13MAPK12NQO2 | |
| SCHEMBL5201377 | 0.77 | MAPK14 (0.63) | MAPK14MAPK11MAPK13MAPK12NQO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007082079-A2 | PIPERIDINE AMIDE DERIVATIVES AS PROTEIN KINASE INHIBITORS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2007-07-19 | — | — | WO | disclosed |